Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MDS Pharma Services has expanded its presence in the Phoenix area with a new 300-bed Phase I facility in nearby Tempe, Arizona. In addition to a specialized area for conducting cardiac safety trials, the new facility also offers specialized ophthalmic capabilities, as well as a range of other specialty Phase I services.
Subscribe to our email newsletter
The $25 million facility more than doubles the previous MDS Phase I capacity in Phoenix to 420 total beds to meet the growing needs of its pharmaceutical and biotech clients. Part of an extensive global network of European and North American Phase I locations, the new facility brings the MDS Pharma Services global total to more than 1,100 beds.
Purpose-built from the ground up to be a Phase I clinic, the new facility has a state-of-the art clinical lab and secure pharmacy, comfortable accommodations for study participants and well-appointed areas for visiting clients. The workforce for the new facility is drawn from the same experienced team that operated the earlier MDS Pharma Services Phoenix clinic, where they achieved a better than 97% on-time study start-up record.